Therapeutic Efficiency of an External Chinese Herbal Formula of Mammary Precancerous Lesions by BATMAN-TCM Online Bioinformatics Analysis Tool and Experimental Validation

Guijuan Zhang, Xuefeng Jiang, Yu‐Sheng Liu, Xiaoqian Hao, Yurong Wang, Xianxin Yan, Naijun Yuan, Yi Ma, Min MaEvidence-based 2019 · DOI

TL;DR

This study investigates Ruyan Neixiao Cream (RYNXC), a traditional Chinese herbal formula, for its potential to treat mammary precancerous lesions. By combining bioinformatics analysis with experimental validation, researchers identified key molecular targets and demonstrated RYNXC's ability to downregulate critical genes and proteins involved in the progression of these lesions, suggesting its promise as an external therapeutic agent.

What Problem Does This Paper Address?

Breast cancer remains a significant health concern, and while advancements in treatment exist, many current therapies, like chemotherapy and endocrine therapy, come with toxic side effects. Targeted drugs, while promising, often only inhibit parts of complex signaling pathways and can be expensive. Furthermore, the development of breast cancer is a multistage process involving precancerous lesions, which represent a critical window for intervention. Traditional Chinese Medicine (TCM) offers a rich source of potential treatments, but understanding the molecular mechanisms of complex herbal formulas has been challenging due to the intricate interplay of numerous ingredients. This paper aims to bridge this gap by elucidating the therapeutic mechanism of RYNXC, a TCM formula used for precancerous lesions, using a modern bioinformatics approach coupled with experimental validation.

Methods

The researchers employed a two-pronged approach:

  1. Bioinformatics Analysis (BATMAN-TCM): They utilized the BATMAN-TCM (Bioinformatics Analysis Tool for Molecular mechANism of TCM) online platform to predict potential drug-target interactions, biological pathways, and associated diseases for the nine herbs comprising RYNXC. This involved inputting the herbs into the tool, which then ranked potential targets based on similarity to known drug-target interactions. The results were used to construct an "ingredients-targets-diseases" network.
  2. Experimental Validation:
    • In Vitro Studies: They used MCF-10AT cells, a model for breast precancerous lesions, to assess the effects of RYNXC. This involved cell viability assays (MTT assay) to determine its impact on cell proliferation and quantitative reverse transcription PCR (RT-PCR) and Western blot analysis to measure the mRNA and protein expression levels of key genes (ESR1, PGR, PTGS2, EGFR, Src) and proteins (ER-α, PR, EGFR, COX2, Src).
  3. In Vivo Studies: A rat model of breast precancerous lesions was established using DMBA, estrogen, and progesterone. Rats were then treated with different doses of RYNXC, a blank matrix, or Tamoxifen (a known therapeutic agent). Histological examination (Hematoxylin-Eosin staining) was performed to observe pathological changes. RT-PCR and Western blot were also used to analyze the expression of the same key genes and proteins in the rat breast tissues.

Datasets

  • BATMAN-TCM Database: This online tool integrates data from DrugBank, KEGG (Kyoto Encyclopedia of Genes and Genomes), and TTD (Therapeutic Target Database) for predicting drug-target interactions and pathways.
  • MCF-10A, MCF-7, and MDA-MB-231 cell lines: Standard cell lines used in breast cancer research.
  • SD Rats: A standard animal model for preclinical studies.

The paper does not introduce new benchmark datasets.

Key Insights and Ideas

  • TCM Complexity Unraveled by Bioinformatics: The study highlights the power of bioinformatics tools like BATMAN-TCM in dissecting the complex molecular mechanisms of multi-component herbal formulas, offering a systematic way to understand their therapeutic actions.
  • RYNXC Targets Key Cancer Pathways: The prediction and experimental validation converged on several critical molecular targets (ESR1, PGR, PTGS2, EGFR, Src) known to be involved in breast cancer development and progression.
  • Dual Action at Gene and Protein Levels: RYNXC demonstrated efficacy not only at the mRNA level but also by downregulating the corresponding protein expression, suggesting a comprehensive inhibitory effect.
  • Dose-Dependent Efficacy: The experimental results showed that RYNXC's inhibitory effects on cell proliferation and gene/protein expression were dose-dependent, reinforcing its therapeutic potential.
  • Promising External Application: The study's focus on an external application (cream) is significant, as it may offer an alternative with potentially fewer systemic side effects compared to oral medications.

Key Results

  • Bioinformatics Prediction: BATMAN-TCM predicted 1626 potential targets for RYNXC, with ESR1, PGR, EGFR, and Src identified as key targets for breast cancer.
  • In Vitro Efficacy: RYNXC significantly inhibited MCF-10AT cell proliferation in a dose-dependent manner. It also significantly downregulated the mRNA and protein expression of ESR1, PGR, EGFR, PTGS2, and Src in MCF-10AT cells.
  • In Vivo Efficacy: In the rat model, RYNXC treatment significantly reduced the incidence of precancerous lesions and invasive carcinomas. It also significantly decreased the mRNA and protein expression of ESR1, PGR, EGFR, PTGS2, and Src in breast tissues.
  • Comparison to Tamoxifen: High-dose RYNXC showed comparable efficacy to Tamoxifen in downregulating key protein expressions in the rat model.

Limitations and Future Work

  • External Application Mechanism: The authors acknowledge that RYNXC is an external cream, and further research is needed to understand which specific compounds are absorbed through the skin and how they exert their therapeutic effects.
  • Detailed Signaling Pathway Elucidation: While key targets were identified, the study did not delve into the intricate details of the specific signaling pathways and mechanisms affected by RYNXC.
  • Compound-Specific Effects: The study focused on the combined formula. Future work could investigate the individual contributions of specific compounds within RYNXC.
  • Further Exploration of Mechanisms: The authors plan to investigate the biological processes and signaling pathways associated with the identified targets to gain a deeper understanding of RYNXC's therapeutic mechanism. They also aim to identify which compounds are most effective in transdermal delivery.

Summary updated

Abstract

Ruyan Neixiao Cream (RYNXC), a patented Chinese herbal formula, was reported to have the effect of treating mammary precancerous disease. In this study, we predicted the potential targets, pathways, and diseases of the ingredients contained in each herbal of RYNXC and constructed an ingredients-targets-diseases network. Then, we analyzed molecular mechanisms of this Chinese herbal formula by MCF-10AT cells and model rats of breast precancerous lesions. BATMAN-TCM prediction showed that ESR1, PGR, PTGS2, EGFR, and Src were mRNA targets of RYNXC. Our results suggested that RYNXC transdermal fluid downregulated ESR1, PGR, PTGS2, EGFR, and Src expression at gene and protein level in MCF-10AT cells. In the rat breast precancerous lesions model, high and low dose RYNXC could also significantly reduce genes and proteins expression of ESR1, PGR, PTGS2, EGFR, and Src. Taken together these data indicate that RYNXC targets multiple molecules responsible for breast precancerous lesion and is an effective Chinese herbal formula. So RYNXC may be a promising external drug for breast precancerous lesions.
BibTeX
@inproceedings{zhang2019therapeutic,
  author = {Guijuan Zhang and Xuefeng Jiang and Yu‐Sheng Liu and Xiaoqian Hao and Yurong Wang and Xianxin Yan and Naijun Yuan and Yi Ma and Min Ma},
  title = {{Therapeutic Efficiency of an External Chinese Herbal Formula of Mammary Precancerous Lesions by BATMAN-TCM Online Bioinformatics Analysis Tool and Experimental Validation}},
  booktitle = {Evidence-based},
  year = {2019},
  doi = {10.1155/2019/2795010},
}
Figure